Literature DB >> 6351775

Long-term incompatible kidney survival in outbred higher primates without chronic immunosuppression.

F T Thomas, F M Carver, M B Foil, W H Pryor, E W Larkin, W R Hall, C E Haisch, J M Thomas.   

Abstract

Transplantation between non-identical humans has been limited by the requirement for chronic immunosuppression (CI). This study demonstrates in a nonhuman primate model that long-term acceptance of incompatible kidney allografts can be achieved without the use of CI. Following incompatible kidney transplantation, rhesus monkey recipients were given a 5-day course of clinical rabbit antithymocyte globulin (RATG). On day 12, unfractionated donor bone marrow (BM) was infused intravenously. Recipients were monitored for T-cell levels and T-cell subset levels with monoclonal antibodies and for responses in one way MLR. Graft survival in untreated control animals was 9.2 +/- 2.8 days. In six animals given RATG only, all died of rejection at a mean 35.8 +/- 5.7 days. Of five animals given RATG and donor BM (mean 2.5 RhLA mismatches, mean MLC 12.7), four are alive at 150 days, 248 days, 342 days, and 401 days (median 248 days). The ATG-BM infused group showed a prolonged imbalance of their OKT4/OKT8 cell ratio and cellular suppression of MLR responsiveness. The long-term survival obtained in these outbred primates is apparently due to a synergistic immunoregulatory effect induced by the RATG and donor BM. The model described is apparently the first report of long-term survival of outbred higher primates without CI and may represent a technique for producing tolerance without CI in the human.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6351775      PMCID: PMC1353310          DOI: 10.1097/00000658-198309000-00013

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  35 in total

1.  Enhancement of renal allografts in rats and man.

Authors:  M E French; J R Batchelor
Journal:  Transplant Rev       Date:  1972

2.  Allograft enhancement induced by bone marrow cells.

Authors:  A Liegeois; J Charreire; L B Brennan
Journal:  Surg Forum       Date:  1974

3.  Use of low doses of homozygous allogeneic bone marrow cells to induce tolerance with antilymphocyte serum (ALS): tolerance by intraorgan injection.

Authors:  A P Monaco; J J Gozzo; M L Wood; A Liegeois
Journal:  Transplant Proc       Date:  1971-03       Impact factor: 1.066

4.  Choice of animal species for modern transplantation research.

Authors:  H Balner
Journal:  Transplant Proc       Date:  1974-12       Impact factor: 1.066

5.  Quantitative studies on tissue transplantation immunity. IX. Induction of tolerance with antilymphocytic serum.

Authors:  E M Lance; P Medawar
Journal:  Proc R Soc Lond B Biol Sci       Date:  1969-07-22

6.  Immunogenetic studies of rhesus monkeys. II. The H, I, J, K and L blood group systems.

Authors:  C R Duggleby; C Blystad; W H Stone
Journal:  Vox Sang       Date:  1971-02       Impact factor: 2.144

7.  Unresponsiveness to skin allografts induced by tissue extracts and antilymphocytic serum.

Authors:  L Brent; J A Hansen; P J Kilshaw
Journal:  Transplant Proc       Date:  1971-03       Impact factor: 1.066

Review 8.  The histocompatibility complex of rhesus monkeys. 3. Evidence for a major MLR locus and histocompatibility-linked Ir genes.

Authors:  H Balner; M E Dorf; M L de Groot; B Benacerraf
Journal:  Transplant Proc       Date:  1973-12       Impact factor: 1.066

9.  Immunogenetic studies of rhesus monkeys. I. The G blood group system.

Authors:  C R Duggleby; W H Stone
Journal:  Vox Sang       Date:  1971-02       Impact factor: 2.144

10.  Enhanced survival of canine renal allografts of ALS- treated dogs given bone marrow.

Authors:  D T Caridis; A Liegeois; I Barrett; A P Monaco
Journal:  Transplant Proc       Date:  1973-03       Impact factor: 1.066

View more
  9 in total

Review 1.  Mixed chimerism and split tolerance: mechanisms and clinical correlations.

Authors:  David P Al-Adra; Colin C Anderson
Journal:  Chimerism       Date:  2011 Oct-Dec

Review 2.  Lymphodepletional strategies in transplantation.

Authors:  Eugenia Page; Jean Kwun; Byoungchol Oh; Stuart Knechtle
Journal:  Cold Spring Harb Perspect Med       Date:  2013-07-01       Impact factor: 6.915

Review 3.  Bone marrow augmentation in renal transplant recipients.

Authors:  R Shapiro; T E Starzl
Journal:  Transplant Proc       Date:  1998-06       Impact factor: 1.066

4.  Induction of Pancreatic Islet Graft Acceptance: The Role of Antigen Presenting Cells.

Authors:  Camillo Ricordi; Suzanne T Ildstad; Thomas E Starzl
Journal:  Transplant Sci       Date:  1992-04

Review 5.  Converting nonhuman primate dendritic cells into potent antigen-specific cellular immunosuppressants by genetic modification.

Authors:  Asiedu Clement; Alexander Pereboev; David T Curiel; Sai Sai Dong; Anne Hutchings; Judith M Thomas
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

6.  Poor immune reconstitution after four or five major HLA antigens mismatched T cell-depleted allogeneic and autologous stem cell transplantation.

Authors:  J Mattsson; M Uzunel; M Remberger; L Tammik; B Omazic; V Levitsky; J Z Zou; P Hentschke; O Ringdén
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

Review 7.  Induction of transplantation tolerance in non-human primate preclinical models.

Authors:  Douglas A Hale; Kiran Dhanireddy; David Bruno; Allan D Kirk
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

8.  Combined simultaneous kidney/bone marrow transplantation.

Authors:  R Shapiro; A S Rao; P Fontes; A Zeevi; M Jordan; V P Scantlebury; C Vivas; H A Gritsch; R J Corry; F Egidi
Journal:  Transplantation       Date:  1995-12-27       Impact factor: 4.939

9.  Long-term survival of donor-specific pancreatic islet xenografts in fully xenogeneic chimeras (WF rat----B10 mouse).

Authors:  Y J Zeng; C Ricordi; A Tzakis; H L Rilo; P B Carroll; T E Starzl; S T Ildstad
Journal:  Transplantation       Date:  1992-02       Impact factor: 4.939

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.